On support of this notion, in melanoma xenografts the reduction of tumor growth by ETBR blockade using the selective ETBR antagonist [25], was accompanied by reduction of tumor microvessel density, HIF-1α, HIF-2α and VEGF expression and a concomitant increase of PHD2 levels. Here, EGLN1 is linked to melanoma.